First patient dosed in a proof-of-concept study of Yaqrit’s advanced microbiome ...

Data expected H2 2026Rare liver disease with no approved treatment, typically concurrent with Inflammatory Bowel Disease (IBD)Second YAQ001 clinical study following successful cirrhosis trial LONDON, ...